文献速递肾移植肾小球疾病肾血管病与高血压

肾移植受者并发症遗传检测面板的开发

Developing a genetic testing panel for evaluation of morbidities in kidney transplant recipients.
PubMed 文献 · Kidney Int · 2024-03-21

研究开发了一个包含355个基因的移植并发症基因面板,并在1590例肾移植受者中利用外显子测序数据评估。9.1%的受者检出与心血管病、恶性肿瘤、免疫缺陷和血栓倾向相关的单基因病变异,这些发现对移植管理有重要临床意义。

要点

  • 移植并发症基因面板在9.1%肾移植受者中检出单基因病变异
  • 9.9%受者检出肾脏及泌尿生殖系统单基因病诊断变异,其中25.9%未临床诊断
  • 遗传发现可指导监测、预防、治疗及免疫抑制调整等临床决策

核心结论

  • 在肾移植受者中,除肾脏疾病诊断外,序列注释可识别与常见移植后并发症相关的单基因病,对临床管理有重要指导意义。

研究设计与样本

  • 开发包含355个基因的移植并发症基因面板,涵盖心血管代谢病、免疫缺陷、恶性肿瘤和血栓倾向。
  • 利用1590例肾移植受者的外显子测序数据评估该面板,并注释肾脏及泌尿生殖系统单基因病基因和ACMG次要发现v3.2。

主要发现

  • 9.9%(158/1590)的肾移植受者检出37个肾脏及泌尿生殖系统单基因病基因的诊断变异,其中25.9%(41/158)未获临床诊断。
  • 移植并发症基因面板在9.1%(144/1590)的受者中检出56种单基因病的诊断变异。
  • 在1590例受者中,心血管病、恶性肿瘤、免疫缺陷和血栓倾向相关变异分别检出5.1%(81例)、2.1%(34例)、1.8%(29例)和0.2%(3例)。
  • 这些病例中约一半存在与基因变异一致的表型。

关键数值与推荐

  • 遗传发现可使医生在6.3%(9/144)的病例中设定特定风险因素目标。
  • 遗传发现可安排97.2%(140/144)的病例进行强化监测。
  • 遗传发现可采用预防措施者占13.2%(19/144),指导疾病特异性治疗者占63.9%(92/144)。
  • 遗传发现可启动专科转诊者占90.3%(130/144),可调整免疫抑制方案者占56.9%(82/144)。

临床怎么用

  • 将移植并发症遗传诊断纳入移植前和移植后管理,有助于实现个体化诊疗。
  • 基因面板可识别未临床诊断的单基因肾病及移植后并发症高风险者,指导监测和预防干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiovascular disease, infection, malignancy, and thromboembolism are major causes of morbidity and mortality in kidney transplant recipients (KTR). Prospectively identifying monogenic conditions associated with post-transplant complications may enable personalized management. Therefore, we developed a transplant morbidity panel (355 genes) associated with major post-transplant complications including cardiometabolic disorders, immunodeficiency, malignancy, and thrombophilia. This gene panel was then evaluated using exome sequencing data from 1590 KTR. Additionally, genes associated with monogenic kidney and genitourinary disorders along with American College of Medical Genetics (ACMG) secondary findings v3.2 were annotated. Altogether, diagnostic variants in 37 genes associated with Mendelian kidney and genitourinary disorders were detected in 9.9% (158/1590) of KTR; 25.9% (41/158) had not been clinically diagnosed. Moreover, the transplant morbidity gene panel detected diagnostic variants for 56 monogenic disorders in 9.1% KTRs (144/1590). Cardiovascular disease, malignancy, immunodeficiency, and thrombophilia variants were detected in 5.1% (81), 2.1% (34), 1.8% (29) and 0.2% (3) among 1590 KTRs, respectively. Concordant phenotypes were present in half of these cases. Reviewing implications for transplant care, these genetic findings would have allowed physicians to set specific risk factor targets in 6.3% (9/144), arrange intensive surveillance in 97.2% (140/144), utilize preventive measures in 13.2% (19/144), guide disease-specific therapy in 63.9% (92/144), initiate specialty referral in 90.3% (130/144) and alter immunosuppression in 56.9% (82/144). Thus, beyond diagnostic testing for kidney disorders, sequence annotation identified monogenic disorders associated with common post-transplant complications in 9.1% of KTR, with important clinical implications. Incorporating genetic diagnostics for transplant morbidities would enable personalized management in pre- and post-transplant care.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Ma BM, Elefant N, Tedesco M, et al. Developing a genetic testing panel for evaluation of morbidities in kidney transplant recipients. Kidney Int. 2024. PMID: 38521406. doi:10.1016/j.kint.2024.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。